항갑상선제 시장 : 세계 예측(2026-2032년)

The Antithyroid Preparations Market is projected to grow by USD 2.57 billion at a CAGR of 5.31% by 2032.

Antithyroid Preparations: Executive Overview

Antithyroid preparations are medicines used to reduce thyroid hormone production, primarily in hyperthyroidism and Graves' disease. Clinical selection depends on disease severity, patient age, pregnancy status, liver function, comorbidities, treatment goals, and local prescribing guidance. Common therapeutic approaches include thionamides, radioactive iodine, and surgery, although these options differ in mechanism, monitoring requirements, contraindications, and suitability for individual patients.

Treatment Pathways Are Becoming More Individualized

The treatment landscape is shifting from one-size-fits-all prescribing toward risk-based care. Clinicians increasingly weigh remission prospects, adverse-event risks, pregnancy considerations, definitive-treatment preferences, and the need for long-term biochemical monitoring. Safety surveillance remains central because antithyroid medicines can cause clinically important reactions, including agranulocytosis and hepatotoxicity. Clear patient education about warning symptoms and prompt laboratory assessment is therefore integral to responsible use.

Artificial Intelligence Supports Monitoring and Clinical Decision-Making

Artificial intelligence can strengthen antithyroid-care workflows by identifying patients who may need thyroid-function testing, flagging medication-related risk patterns, supporting interpretation of serial laboratory results, and helping prioritize follow-up. Its value is cumulative when integrated with electronic records, pharmacy data, clinical guidelines, and patient-reported symptoms. Human oversight remains essential because treatment decisions require contextual judgment, validated evidence, privacy safeguards, and careful management of algorithmic bias.

Regional Insights: Access, Monitoring, and Care Delivery Differ

North America generally emphasizes guideline-driven management, laboratory monitoring, and shared decision-making, while Latin America faces uneven access and differences in specialist availability. Europe combines mature clinical guidance with varied national reimbursement and prescribing systems. The Middle East is shaped by expanding specialist capacity, referral patterns, and healthcare-system variation. Africa continues to encounter diagnostic, laboratory, and medicine-access constraints in several settings. Asia-Pacific spans highly developed systems and rapidly expanding care networks, making workforce capacity, affordability, and continuity of monitoring important priorities.

Group Insights: Regional Blocs Shape Standards and Access

ASEAN markets reflect substantial diversity in healthcare financing, specialist access, and regulatory implementation. BRICS members differ widely in manufacturing capacity, public procurement, diagnostic infrastructure, and treatment pathways. The European Union benefits from shared regulatory principles but retains national differences in reimbursement and service delivery. G7 systems generally have stronger clinical infrastructure and pharmacovigilance capabilities, though affordability and care coordination remain relevant. GCC countries often combine well-resourced urban services with a focus on specialist-led care, while NATO members span diverse health systems and preparedness priorities that influence supply resilience and continuity of treatment.

Country Insights: Distinct Health-System Priorities

Australia and Canada prioritize guideline-based care across geographically dispersed populations. Brazil and Mexico must address regional disparities in specialist access and diagnostic follow-up. China and India combine substantial clinical demand with differences between urban and rural services. France, Germany, Italy, Spain, and the United Kingdom operate within established European care frameworks while differing in reimbursement, referral pathways, and prescribing practice. Japan and South Korea emphasize specialist monitoring and structured healthcare delivery. Russia's care environment is shaped by domestic access, procurement, and regional service variation. The United States places strong emphasis on adverse-event monitoring, specialist care, and treatment choice, alongside persistent affordability and access considerations.

Priorities for Leaders: Strengthen Safety, Access, and Continuity

Industry leaders should align product strategy with evidence-based treatment pathways and provide practical tools for thyroid-function monitoring, adverse-event recognition, and adherence support. Partnerships with clinicians, pharmacies, laboratories, and public health systems can improve continuity of care, particularly where specialist access is limited. Digital and AI-enabled services should be introduced with clinical validation, transparent governance, cybersecurity controls, and human review. Supply planning should prioritize quality assurance, regulatory compliance, and resilience across diverse procurement channels. Patient-facing education should use clear language and reinforce the need to seek urgent evaluation for serious warning symptoms.

Research Methodology: Evidence-Led Market Assessment

This executive summary applies a structured review of established clinical practice, medicine-safety principles, healthcare-system characteristics, regulatory considerations, and regional access conditions relevant to antithyroid preparations. The assessment integrates the specified regional, group, and country geographies without using market estimates, market sizing, market shares, forecasts, or company-specific claims. Interpretations are framed as qualitative insights and should be validated against current national guidelines, regulatory communications, pharmacovigilance findings, and local prescribing information before operational use.

Conclusion: Safe, Context-Aware Management Remains Central

The antithyroid preparations landscape is defined by individualized treatment, vigilant safety monitoring, and uneven access to diagnosis and follow-up. Regional and country differences make adaptable care models essential, while artificial intelligence offers useful support for surveillance and workflow prioritization when properly governed. Sustainable progress depends on evidence-based prescribing, reliable diagnostics, patient education, resilient supply, and coordination among clinicians, regulators, health systems, and communities.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Antithyroid Preparations Market, by Drug Type

• 7.1. Introduction
• 7.2. Carbimazole
• 7.3. Methimazole
• 7.4. Propylthiouracil

8. Antithyroid Preparations Market, by Product Form

• 8.1. Introduction
• 8.2. Injectables
• 8.3. Liquids
• 8.4. Tablets

9. Antithyroid Preparations Market, by Product Type

• 9.1. Introduction
• 9.2. Branded
• 9.3. Generic

10. Antithyroid Preparations Market, by Indication

• 10.1. Introduction
• 10.2. Graves Disease
• 10.3. Toxic Nodular Goiter

11. Antithyroid Preparations Market, by End User

• 11.1. Introduction
• 11.2. Clinics
• 11.3. Home Care
• 11.4. Hospitals

12. Antithyroid Preparations Market, by Distribution Channel

• 12.1. Introduction
• 12.2. Hospital Pharmacy
• 12.3. Online Pharmacy
• 12.4. Retail Pharmacy

13. Antithyroid Preparations Market, by Region

• 13.1. Introduction
• 13.2. Asia-Pacific
• 13.3. North America
• 13.4. Latin America
• 13.5. Europe
• 13.6. Middle East
• 13.7. Africa

14. Antithyroid Preparations Market, by Group

• 14.1. Introduction
• 14.2. ASEAN
• 14.3. GCC
• 14.4. European Union
• 14.5. BRICS
• 14.6. G7
• 14.7. NATO

15. Antithyroid Preparations Market, by Country

• 15.1. Introduction
• 15.2. United States
• 15.3. Canada
• 15.4. Mexico
• 15.5. Brazil
• 15.6. United Kingdom
• 15.7. Germany
• 15.8. France
• 15.9. Russia
• 15.10. Italy
• 15.11. Spain
• 15.12. China
• 15.13. India
• 15.14. Japan
• 15.15. Australia
• 15.16. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. Market Concentration Analysis, 2025
  • 16.2.1. Concentration Ratio (CR)
  • 16.2.2. Herfindahl Hirschman Index (HHI)
• 16.3. Recent Developments & Impact Analysis, 2025
• 16.4. Product Portfolio Analysis, 2025
• 16.5. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbott Laboratories
• 17.2. Amneal Pharmaceuticals LLC
• 17.3. Aurobindo Pharma Ltd.
• 17.4. Bayer AG
• 17.5. Bio-T Ltd.
• 17.6. Cadila Healthcare Ltd.
• 17.7. Cipla Limited
• 17.8. Dr. Reddy's Laboratories Ltd.
• 17.9. Emcure Pharmaceuticals Ltd.
• 17.10. Gland Pharma Ltd.
• 17.11. GlaxoSmithKline plc
• 17.12. Haffkine Bio-Pharmaceutical Corporation Ltd.
• 17.13. Intas Pharmaceuticals Ltd.
• 17.14. Ipca Laboratories Ltd.
• 17.15. Lannett Company, Inc.
• 17.16. Lupin Limited
• 17.17. Merck & Co., Inc.
• 17.18. Mylan N.V.
• 17.19. Novartis International AG
• 17.20. Orion Corporation
• 17.21. Pfizer Inc.
• 17.22. Piramal Enterprises Ltd.
• 17.23. Sanofi S.A.
• 17.24. Strides Pharma Science Ltd.
• 17.25. Sun Pharmaceutical Industries Ltd.
• 17.26. Teva Pharmaceutical Industries Ltd.
• 17.27. The Procter & Gamble Company
• 17.28. Torrent Pharmaceuticals Ltd.
• 17.29. Uni-Sankyo Ltd.
• 17.30. Wockhardt Ltd.

18. Key Experts